Dupilumab: all 174 studies that test it

Page 2 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.

• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)CompletedNCT02134028Phase 3Results posted
• Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)CompletedNCT01979016Phase 2Results posted
• Open-label Study of Dupilumab in Patients With Atopic DermatitisCompletedNCT01949311Phase 3Results posted
• An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of SinusitisCompletedNCT01920893Phase 2Results posted
• Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT01859988Phase 2Results posted
• An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled AsthmaCompletedNCT01854047Phase 2Results posted
• Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)CompletedNCT01639040Phase 2Results posted
• Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic DermatitisCompletedNCT01548404Phase 2Results posted
• Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompletedNCT01312961Phase 2Results posted
• Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsActive, not recruitingNCT07646548Phase 1
• Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With DupilumabWithdrawnNCT07187089Phase 4
• Dupixent Study for Alternate AdministrationActive, not recruitingNCT06750471Phase 4
• A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)CompletedNCT06687980Phase 3
• A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)CompletedNCT06687967Phase 3
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaActive, not recruitingNCT06572228Phase 4
• Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic DermatitisCompletedNCT06509243Not applicable
• Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid SprayWithdrawnNCT06461949Phase 3
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06461897Phase 3
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingNCT06389136Phase 3
• Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyActive, not recruitingNCT06369467Phase 1
• Dupilumab for Eosinophilic Esophagitis With Severe StricturesActive, not recruitingNCT06352073Phase 4
• Early-onset Dupilumab Effects in CRSwNPWithdrawnNCT06188871Phase 4
• Dupilumab De-escalation in Pediatric Atopic DermatitisTerminatedNCT06116526Phase 4
• A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)Active, not recruitingNCT06101095Phase 4
• The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity ReactionCompletedNCT06012448Phase 4
• A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic DermatitisActive, not recruitingNCT05983068Phase 4
• Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy AdultsCompletedNCT05976386Phase 1
• A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.CompletedNCT05976373Phase 1
• A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy ParticipantsCompletedNCT05976360Phase 1
• A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingNCT05942222Phase 4
• A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May HaveActive, not recruitingNCT05831176Phase 2
• A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))Active, not recruitingNCT05731128Phase 2
• Dupilumab Effects Against Aeroallergen ChallengeActive, not recruitingNCT05720325Phase 2
• Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in ChinaCompletedNCT05680298Phase 4
• Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in ChinaCompletedNCT05624112Phase 4
• Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory DiseaseActive, not recruitingNCT05575037Phase 2
• Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingNCT05535738Phase 2/3
• IL-4 and Insulin Resistance for Treatment of Patients With Atopic DermatitisCompletedNCT05372003Early Phase 1
• Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and AdolescentsActive, not recruitingNCT05347771Phase 2
• Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.Status unknownNCT05265234Phase 4
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaActive, not recruitingNCT05097287Phase 4
• Mechanisms of Dupilumab in AERDCompletedNCT05031455Phase 2
• Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in ChildrenStatus unknownNCT04996485Phase 4
• Dupilumab in the Treatment of KeloidsCompletedNCT04988022Phase 4
• NMF-CsA-Dupi TrialStatus unknownNCT04878770Not applicable
• Olfactory Outcomes of Dupilumab Treatment for Nasal PolyposisCompletedNCT04869436Phase 4
• Dupilumab in Japanese Patients With Atopic DermatitisCompletedNCT04678882Phase 3
• Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular EczemaActive, not recruitingNCT04600362Phase 2
• Dupilumab for Prevention of Recurrence of CRSwNP After ESSCompletedNCT04596189Phase 4
• An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic DermatitisStatus unknownNCT04520308Phase 4
• Dupilumab in Severe Chronic Hand EczemaStatus unknownNCT04512339Phase 2
• Effect of Dupilumab on Aspirin IntoleranceStatus unknownNCT04442256Phase 4
• Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal PolyposisActive, not recruitingNCT04430179Phase 2
• Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)CompletedNCT04362501Phase 2
• The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab TreatmentCompletedNCT04358224Phase 4
• Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized SclerodermaCompletedNCT04200755Phase 2
• Dupilumab Impact on Skin Resident Memory T CellsStatus unknownNCT03983460Not applicable
• Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.CompletedNCT03884842Phase 3
• Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical CorticosteroidsCompletedNCT03861455Phase 2
• Efficacy and Safety Study of Dupilumab in Patients With Persistent AsthmaCompletedNCT03782532Phase 3
• Cholinergic Urticaria - Efficacy of DupilumabCompletedNCT03749148Phase 2
• Dupilumab in Chronic Spontaneous UrticariaCompletedNCT03749135Phase 2
• Investigating Dupilumab's Effect in Asthma by GenotypeActive, not recruitingNCT03694158Phase 4
• Effect of Dupilumab on Sleep Apnea in Patients With RhinosinusitisTerminatedNCT03675022Early Phase 1
• Dupilumab for Aspirin-exacerbated Respiratory DiseaseCompletedNCT03595488Phase 2
• Study of REGN3500 and Dupilumab in Patients With AsthmaCompletedNCT03112577Phase 1
• Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)CompletedNCT02647086Phase 1
• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Active, not recruitingNCT02612454Phase 3
• Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male SubjectsCompletedNCT01537653Phase 1
• Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy SubjectsCompletedNCT01537640Phase 1
• Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy VolunteersCompletedNCT01484600Phase 1
• Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic DermatitisCompletedNCT01385657Phase 1
• Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisCompletedNCT01259323Phase 1
• Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersCompletedNCT01015027Phase 1

← Dupilumab overview